CSPC Pharmaceutical Reports Updated Phase III Overall Survival Results
CSPC Pharmaceutical reported updated Phase III overall survival results for anbenitamab in HER2-positive advanced gastric cancer.
CSPC Pharmaceutical reported updated Phase III overall survival results for anbenitamab in HER2-positive advanced gastric cancer.